Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development.
It is a $121B healthcare company. Revenue grew 3.1% over the last year, it keeps 19¢ of every dollar of sales as profit, and its net debt equals ~3.0 years of free cash flow. It trades at 13.0× earnings — near the lowest of its own history.
- Website
- bms.com
- Location
- Princeton, NJ
- Employees
- 32 500
- Sector
- Healthcare
- Founded
- 1858
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong valuation, profitability and quality; Growth lags behind.
Valuation90
- P/E vs own history10th pct · 25/25
- FCF yield9.5% · 25/25
- P/S2.5x · 20/25
- EV/EBITDA10.3x · 20/25
Growth37
- Revenue CAGR1.0% · 6/25
- Net income CAGR0.2% · 6/25
- EPS CAGR ~5Yn/a · 0/25
- Fwd implied growth39.3% · 25/25
Profitability82
- ROIC13.3% · 12/25
- ROE46.8% · 25/25
- Net margin18.9% · 20/25
- Operating margin25.5% · 25/25
Health59
- Altman Z2.16 · 18/25
- Current ratio1.53 · 18/25
- Interest coverage9.5x · 18/25
- Net cash / debtD/A 38% · 5/25
Quality95
- Piotroski F8/9 · 25/25
- Beneish M-2.85 · 25/25
- FCF conversion123% · 25/25
- Margin stabilityσ 6.2% · 20/25
Moat63
- ROIC >12% years6/10 yrs · 13/25
- Median gross margin71.7% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst -21.2% · 0/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2023FinancialBest year on record$8.03B net income
- FY2018FinancialBecame debt-freecash now exceeds total debt
- FY2016FinancialFirst recorded profitable year$4.46B net income
- FY2016FinancialRevenue already above $10B$19.4B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2007ProductThis was part of a business strategy launched in 2007 to transform the company from a large, diversified…
- 2005MilestonePenicillin production at the East Syracuse plant ended in 2005
- 1989MilestoneBristol-Myers and Squibb merged and became Bristol-Myers Squibb
- 1945MilestoneAnd entered the civilian antibiotics market
- 1943AcquisitionBristol-Myers acquired Cheplin Biological Laboratories, a producer of acidophilus milk in East Syracuse,…
- 1901ProductThe company introduced its first nationally recognized product Sal Hepatica, a laxative mineral…
- 1895MilestoneThe company officially became E.R
- 1887AcquisitionHamilton College graduates William McLaren Bristol and John Ripley Myers purchased the Clinton…
- 1858FoundedThe Squibb corporation was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York after resigning from his…
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (71.7%)
- Strong cash conversion — FCF is 23.3% of revenue
- Interest covered 9.5× by operating earnings
- Piotroski F-Score 8/9 — fundamentally strong checklist
Watch-outs
- Loss-making in 2 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+3.1% YoY
- Profitable — makes more than it spends$9.28B TTM
- Profit growing — earnings are higher than last year+5.5% YoY
- Generates cash — cash left after running and investing$11.4B TTM
- Debt under control — could handle its obligations~3.0y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$121B market cap
- Not printing shares — share count not ballooning — you keep your slice-9.8% shares over ~5y
- Proven track record — years of profitability behind it8/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 2.2 — grey
- Pays a dividend — returns cash to shareholdersyield 6.28%
- Valuation not extreme — price not wildly above earningsP/E 13.0
Peer comparisonBristol-Myers Squibb Co. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| BMY this company | $120.8B | 13.0 | +3.1% | 18.9% | Solid |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: BMY vs LLY · BMY vs JNJ · BMY vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/BMY
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of BMY on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $59.14 · market cap $121B.